I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
NCT05537922
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
I3LUNG is an international project aiming to develop a medical device to predict immunotherapy efficacy for NSCLC patients using the integration of multisource data (real word and multi-omics data). This objective will be reached through a retrospective - setting up a transnational platform of available data from 2000 patients - and a prospective - multi-omics prospective data collection in 200 NSCLS patients - study phase.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non Small Cell Lung Cancer
- Lung Cancer Metastatic
- Lung Cancer, Nonsmall Cell
- Lung Adenocarcinoma
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Last updated on ClinicalTrials.gov
- January 6, 2023
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Illinois · 1
- University of Chicago · Chicago, IL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.